查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372753

組織診斷市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品、按應用、技術、地區和競爭細分。

Tissue Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Application, By Technology, By Region and Competition.
出版日期: | 出版商: TechSci Research | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球組織診斷市場價值為 51.1 億美元，預計在預測期內將強勁成長，預計到 2028 年年複合成長率為 7.36%。該市場在更廣泛的醫療診斷領域中佔據關鍵地位，包括致力於組織和細胞檢查的各種技術和技術。其主要目標包括疾病的檢測、診斷和監測，並著重於癌症檢測和評估。支撐市場成長的幾個關鍵因素包括全球癌症發生率不斷上升、人口老化不斷擴大以及對精準和個人化醫療的需求不斷成長。

組織診斷技術涵蓋免疫組織化學、原位雜合技術、數位病理學和特殊染色等一系列方法。這些工具使病理學家和醫療保健從業者能夠識別疾病標記、評估組織不規則性並為患者制定最佳治療方法。值得注意的是，將人工智慧 (AI) 和機器學習整合到組織診斷中，提高了分析的精確度和效率，促進更快速、更準確的疾病檢測和分類。

市場概況
預測期 2024-2028
2022 年市場規模 51.1億美元
2028 年市場規模 78.3億美元
2023-2028 年年複合成長率 7.36%
成長最快的細分市場 儀器和試劑
最大的市場 北美洲

組織診斷市場仍處於不斷發展的狀態，不斷進行研究和開發，旨在提高診斷準確性、擴大應用範圍和最佳化患者護理。因此，它是全球現代醫療保健系統的關鍵組成部分。

主要市場促進因素

癌症發生率增加

癌症發生率的增加是全球組織診斷市場的重要驅動力。癌症已成為一個緊迫的全球健康問題，世界各地的發病率不斷上升。癌症病例的激增凸顯了組織診斷在疾病檢測、表徵和治療計劃中的關鍵作用。組織診斷技術，例如組織病理學和免疫組織化學，對於確認癌症診斷、確定癌症類型和分期以及評估疾病的侵襲性至關重要。由於生活方式的改變、人口老化、環境因素和遺傳傾向等因素，癌症發生率持續攀升，對組織診斷的需求也隨之增加。此外，基於組織的分子測試的進步使得能夠識別指導標靶治療的特定生物標記，進一步強調了組織診斷在癌症治療中的重要性。正在進行的與癌症的鬥爭需要準確、及時的組織分析，這使得組織診斷成為對抗這種廣泛而複雜的疾病不可或缺的工具。因此，在全球範圍內對有效癌症診斷和管理的需求不斷成長的推動下，組織診斷市場預計將持續成長。

技術進步

技術進步在推動全球組織診斷市場的創新和成長方面發揮了關鍵作用。這些技術的發展顯著提高了組織診斷的精確度、效率和可近性，使其在醫療保健領域比以往任何時候都更加不可或缺。數位病理學就是這樣的進步之一，它允許組織病理學切片的數位化，實現遠端訪問，並促進病理學家之間的協作諮詢。人工智慧 (AI) 和機器學習也已經成為遊戲規則的改變者，它們可以實現圖像分析自動化、提高診斷準確性，並幫助識別人眼可能錯過的微妙模式和生物標記。此外，將聚合酶鏈反應（PCR）和次世代定序（NGS）等分子技術整合到組織診斷中可以檢測特定的基因突變、基因表現譜和蛋白質標記，有助於精確的疾病表徵和個人化的治療決策。這些技術進步不僅加快了診斷過程，也為更全面、更有針對性的病患照護鋪平了道路。隨著技術的不斷發展，組織診斷可能會變得更加複雜，成為多種疾病的診斷和管理不可或缺的一部分，進一步推動全球組織診斷市場的發展。

增加醫療支出

醫療保健支出的增加是影響全球組織診斷市場成長的重要因素。在全球範圍內，政府、醫療機構和個人正在將大部分財政資源投入醫療保健服務和技術上。醫療保健支出的激增反映出人們越來越意識到早期疾病檢測和精確診斷的重要性，特別是在癌症等複雜疾病的背景下。組織診斷在疾病診斷、分期和治療計劃中發揮關鍵作用，是支出增加的受益者。隨著醫療保健預算的擴大，醫療保健提供者可以投資先進的組織診斷設備、尖端技術和熟練人員，以確保更好的可及性和更高品質的診斷服務。此外，隨著醫療保健領域的研發投入更多的財政資源，組織診斷不斷創新，進而發展出更準確、更有效率的診斷測試和技術。因此，不斷增加的醫療保健支出不僅推動了對組織診斷的需求，而且還為醫療保健行業的這一關鍵領域創造了持續改進和創新的環境，最終透過更早、更準確和更有效的疾病管理使患者受益。

意識和篩檢計劃

意識和篩檢計畫在塑造全球組織診斷市場方面發揮著至關重要的作用。這些措施旨在提高公眾對早期疾病檢測重要性的認知，並鼓勵個人定期進行健康檢查。特別是，針對癌症（包括乳癌、子宮頸癌、大腸癌和攝護腺癌）等疾病的宣傳活動和有組織的篩檢計劃，有助於推動組織診斷的需求。由於這些計劃強調早期診斷的好處，越來越多的人尋求醫療救助，導致需要分析的組織樣本量增加。組織診斷，包括組織病理學和免疫組織化學等技術，是這些篩檢計畫的關鍵組成部分，因為它們可以確認診斷，為疾病進展提供有價值的見解，並指導適當的治療策略。組織診斷技術的進步進一步促進了這些計畫的成功，並提高了疾病檢測的準確性和速度。透過培育積極主動的健康管理和早期干涉文化，意識和篩檢計畫對組織診斷市場的成長做出了重大貢獻，確保疾病在最早、最可治療的階段得到識別和管理，最終改善患者的治療結果並減輕負擔全球醫療保健系統中的晚期疾病。

主要市場挑戰

設備成本高

設備的高成本是全球組織診斷市場的重要限制因素。組織診斷技術，包括先進的影像系統、數位病理掃描儀、分子測試平台和自動化組織處理器，通常價格昂貴。購買和安裝這些機器所需的初始資本投資可能會導致醫療機構的預算緊張，特別是資源有限地區的小型診所和設施。此外，持續的維護和服務成本會增加財務負擔。這個成本因素可能會阻止醫療保健提供者採用或升級組織診斷設備，導致基礎設施過時，進而影響診斷的準確性和效率。此外，當醫療保健提供者透過服務費轉嫁高額設備成本時，患者組織診斷服務的承受能力可能會受到影響。解決設備的高成本問題對於確保全球公平獲得組織診斷至關重要。降低成本的努力，例如開發更具成本效益的診斷平台和公私合作夥伴關係，對於使醫療保健提供者和患者更容易獲得組織診斷至關重要，從而克服市場上的這一重大限制。

發展中地區的可及性有限

發展中地區的可近性有限是全球組織診斷市場面臨的重大挑戰。在發展中國家的許多資源匱乏和服務不足的地區，獲得組織診斷的機會受到各種因素的限制。首先，缺乏設備齊全的醫療保健設施，缺乏必要的基礎設施和熟練的人員來準確地進行組織診斷。其次，診斷設備、試劑和維護的高昂成本可能會讓預算有限的醫療機構望而卻步。第三，地理障礙和交通基礎設施不足可能會阻礙患者到達提供組織診斷服務的醫療中心的能力，特別是在偏遠農村地區。此外，缺乏對早期疾病檢測重要性的認知和教育可能會導致就醫行為延遲。解決發展中地區的可及性有限問題需要多方面的努力，包括投資醫療基礎設施、培養熟練勞動力的培訓計劃、開發負擔得起的攜帶式診斷技術，以及提高認知和鼓勵定期篩檢的公共衛生運動。克服這些可近性挑戰對於確保服務不足地區的個人能夠公平地獲得組織診斷至關重要，從而實現更早的疾病檢測和改善醫療保健結果。

主要市場趨勢

數位病理學與人工智慧整合

數位病理學和人工智慧整合是全球組織診斷市場的變革趨勢。數位病理學涉及傳統玻片的數位化，使病理學家和醫療保健專業人員能夠以電子方式查看和分析高解析度組織病理學影像。從傳統顯微鏡到數位平台的轉變允許遠端存取、簡化協作以及創建大量影像檔案。此外，人工智慧（AI）和機器學習演算法的融合增強了數位病理的診斷能力。人工智慧驅動的影像分析軟體可以幫助病理學家識別和量化組織異常、識別特定的生物標記物，甚至預測疾病結果。這些技術提高了診斷準確性，降低了人為錯誤的風險，並實現了更快的周轉時間，最終實現了更有效率、更精確的組織診斷。此外，人工智慧驅動的預測分析可以透過考慮大量資料集並識別人眼可能錯過的微妙模式，幫助病理學家提出更明智的治療建議。隨著數位病理學和人工智慧的採用不斷成長，它不僅提高了組織診斷的質量，還促進了大規模研究資料庫的開發，並透過遠端病理學向服務不足的地區提供病理服務，使其成為一個關鍵趨勢推進組織診斷領域。

成長中的遠距病理學

遠距病理學是全球組織診斷市場的重要趨勢，徹底改變了病理學服務的提供和取得方式。這種方法涉及由遠離患者或標本來源的病理學家對病理標本（主要是組織病理學圖像）進行遠端諮詢和解釋。遠端病理學利用數位技術和高速網際網路連接將高解析度影像、臨床資料和患者病史傳輸給遠端病理學家進行分析。這一趨勢提供了幾個顯著的優勢，包括改善獲得專業知識和諮詢的機會，而不受地理限制。它增強了病理學家之間的合作，並促進對複雜病例的第二意見，最終導致更準確的診斷和治療決策。此外，事實證明，遠距病理學在服務不足和偏遠地區特別有價值，因為這些地區接觸到經驗豐富的病理學家的機會可能有限。它還使病理學家能夠遠端審查病例，從而支持醫療保健系統有效管理工作量，從而減少週轉時間並增強整體患者護理。隨著對病理服務的需求不斷成長，遠距病理學在解決與獲取、專業知識和及時診斷相關的挑戰方面發揮關鍵作用，使其成為組織診斷領域的變革趨勢。

細分市場洞察

應用洞察

2022 年，組織診斷市場以乳癌領域為主，預計未來幾年將持續擴大。這是由於世界各地癌症盛行率不斷上升、先進技術不斷發展以及研究措施不斷增加。

區域洞察

2022 年，全球組織診斷市場由北美市場主導，預計未來幾年將持續擴大。這是由於癌症病例的不斷增加、癌症技術的不斷發展以及醫療基礎設施的不斷發展。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和次要類型
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰與趨勢概述

第 4 章：客戶之聲

第 5 章：全球組織診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（儀器、試劑、耗材）
    • 按應用（乳腺癌、前列腺癌、胃癌和其他癌症）
    • 按技術（免疫組織化學、原位雜合技術、數位病理學和工作流程管理等）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2022)
  • 產品市場地圖
    • 按產品分類
    • 按應用
    • 依技術
    • 按地區

第 6 章：北美組織診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按應用
    • 依技術
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲組織診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按應用
    • 依技術
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區組織診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按應用
    • 依技術
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第 9 章：南美洲組織診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按應用
    • 依技術
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲組織診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按應用
    • 依技術
    • 按國家/地區
  • MEA：國家分析
    • 阿拉伯聯合大公國組織診斷
    • 沙烏地阿拉伯組織診斷
    • 南非組織診斷

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購
  • 產品開發
  • 最近的發展

第13章：波特的分析

第 14 章：PESTEL 分析

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（據報導）
  • 最近的發展
    • Nanoscribe GmbH & Co. KG
    • Stratasys Ltd.
    • 3D Systems Inc.
    • EOS GmbH
    • Renishaw PLC
    • Exone Company.
    • Formlabs Inc.,
    • Materialise NV.
    • SLM Solutions Group AG
    • Oxferd Performance Materials, Inc.

第 16 章：策略建議

簡介目錄
Product Code: 16130

The Global Tissue Diagnostics Market, valued at USD 5.11 billion in 2022, is poised for robust growth in the forecast period, with an anticipated CAGR of 7.36% through 2028. This market holds a critical position within the broader landscape of healthcare diagnostics, encompassing a diverse array of techniques and technologies dedicated to the examination of tissues and cells. Its primary objectives include the detection, diagnosis, and monitoring of diseases, with a significant focus on cancer detection and assessment. Several key factors underpin the market's growth, including the increasing global incidence of cancer, the expanding aging population, and the growing demand for precise and personalized medicine.

Tissue diagnostics techniques span a range of methods such as immunohistochemistry, in situ hybridization, digital pathology, and special staining, among others. These tools empower pathologists and healthcare practitioners to identify disease markers, assess tissue irregularities, and formulate optimal treatment approaches for patients. Notably, the integration of artificial intelligence (AI) and machine learning into tissue diagnostics is amplifying the precision and efficiency of analyses, facilitating swifter and more accurate disease detection and categorization.

Historically, North America has been a prominent market for tissue diagnostics, driven by high healthcare expenditures and early technology adoption. However, emerging economies in the Asia-Pacific region are increasingly experiencing substantial growth in this sector. This growth is propelled by the expansion of healthcare infrastructure and heightened awareness.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 5.11 Billion
Market Size 2028USD 7.83 Billion
CAGR 2023-20287.36%
Fastest Growing SegmentInstruments and Reagents
Largest MarketNorth America

The tissue diagnostics market remains in a state of continuous evolution, with ongoing research and development endeavors aimed at enhancing diagnostic accuracy, broadening applications, and optimizing patient care. As such, it stands as a pivotal component of modern healthcare systems worldwide.

Key Market Drivers

Increasing Cancer Incidence

The increasing cancer incidence is a significant driver in the Global Tissue Diagnostics Market. Cancer has become a pressing global health concern, with rising incidence rates observed across the world. This surge in cancer cases underscores the critical role of tissue diagnostics in disease detection, characterization, and treatment planning. Tissue diagnostics techniques, such as histopathology and immunohistochemistry, are fundamental in confirming cancer diagnoses, determining cancer type and stage, and assessing the aggressiveness of the disease. As cancer rates continue to climb due to factors like lifestyle changes, aging populations, environmental factors, and genetic predisposition, the demand for tissue diagnostics escalates in parallel. Moreover, advancements in tissue-based molecular testing have enabled the identification of specific biomarkers that guide targeted therapies, further emphasizing the importance of tissue diagnostics in cancer treatment. The ongoing battle against cancer necessitates accurate and timely tissue analysis, making tissue diagnostics an indispensable tool in the fight against this widespread and complex disease. As a result, the tissue diagnostics market is poised for sustained growth, driven by the ever-increasing demand for effective cancer diagnosis and management on a global scale..

Advancements in Technology

Advancements in technology have played a pivotal role in driving innovation and growth in the Global Tissue Diagnostics Market. These technological developments have significantly enhanced the precision, efficiency, and accessibility of tissue diagnostics, making them more indispensable than ever in the field of healthcare. Digital pathology is one such advancement, allowing for the digitization of histopathological slides, enabling remote access, and facilitating collaborative consultations among pathologists. Artificial intelligence (AI) and machine learning have also emerged as game-changers, automating image analysis, improving diagnostic accuracy, and helping identify subtle patterns and biomarkers that might be missed by the human eye. Furthermore, the integration of molecular techniques like polymerase chain reaction (PCR) and next-generation sequencing (NGS) into tissue diagnostics enables the detection of specific genetic mutations, gene expression profiles, and protein markers, aiding in precise disease characterization and personalized treatment decisions. These technological strides have not only expedited the diagnostic process but have also paved the way for more comprehensive and tailored patient care. As technology continues to evolve, tissue diagnostics are likely to become even more sophisticated and integral to the diagnosis and management of a wide range of diseases, further advancing the global tissue diagnostics market.

Increasing Healthcare Expenditure

The increasing healthcare expenditure is a significant factor influencing the growth of the Global Tissue Diagnostics Market. Globally, governments, healthcare institutions, and individuals are dedicating a larger portion of their financial resources to healthcare services and technologies. This surge in healthcare spending reflects the growing awareness of the importance of early disease detection and precise diagnostics, particularly in the context of complex diseases like cancer. Tissue diagnostics, which play a pivotal role in disease diagnosis, staging, and treatment planning, are beneficiaries of this increased expenditure. As healthcare budgets expand, healthcare providers can invest in advanced tissue diagnostic equipment, cutting-edge technologies, and skilled personnel, ensuring better accessibility and higher quality diagnostic services. Moreover, with greater financial resources allocated to research and development in the healthcare sector, there is ongoing innovation in tissue diagnostics, leading to the development of more accurate and efficient diagnostic tests and techniques. The increasing healthcare expenditure is, therefore, not only driving the demand for tissue diagnostics but also fostering an environment of continuous improvement and innovation in this crucial segment of the healthcare industry, ultimately benefiting patients through earlier, more accurate, and more effective disease management.

Awareness and Screening Programs

Awareness and screening programs play a vital role in shaping the Global Tissue Diagnostics Market. These initiatives are designed to raise public consciousness about the importance of early disease detection and encourage individuals to undergo regular health screenings. In particular, awareness campaigns and organized screening programs for diseases such as cancer, including breast, cervical, colorectal, and prostate cancers, have been instrumental in driving the demand for tissue diagnostics. As these programs emphasize the benefits of early diagnosis, more individuals seek medical attention, resulting in an increased volume of tissue samples requiring analysis. Tissue diagnostics, including techniques like histopathology and immunohistochemistry, are critical components of these screening programs, as they confirm diagnoses, provide valuable insights into disease progression, and guide appropriate treatment strategies. The success of these programs is further bolstered by technological advancements in tissue diagnostics, which enhance accuracy and speed in disease detection. By fostering a culture of proactive health management and early intervention, awareness and screening programs contribute significantly to the growth of the tissue diagnostics market, ensuring that diseases are identified and managed at their earliest, most treatable stages, ultimately improving patient outcomes and reducing the burden of advanced diseases on healthcare systems worldwide.

Key Market Challenges

High Cost of Equipment

The high cost of equipment is a significant restraining factor in the Global Tissue Diagnostics Market. Tissue diagnostic technologies, including advanced imaging systems, digital pathology scanners, molecular testing platforms, and automated tissue processors, often come with a substantial price tag. The initial capital investment required to acquire and install these machines can strain the budgets of healthcare institutions, particularly smaller clinics and facilities in resource-constrained regions. Moreover, the ongoing maintenance and service costs can add to the financial burden. This cost factor can deter healthcare providers from adopting or upgrading tissue diagnostic equipment, leading to outdated infrastructure that hampers diagnostic accuracy and efficiency. In addition, the affordability of tissue diagnostic services for patients can be compromised when healthcare providers pass on the high equipment costs through service fees. Addressing the high cost of equipment is essential to ensure equitable access to tissue diagnostics globally. Efforts to reduce costs, such as the development of more cost-effective diagnostic platforms and public-private partnerships, are crucial in making tissue diagnostics more accessible to healthcare providers and patients alike, thereby overcoming this significant restraint in the market.

Limited Accessibility in Developing Regions

Limited accessibility in developing regions is a significant challenge facing the Global Tissue Diagnostics Market. In many low-resource and underserved areas of developing countries, access to tissue diagnostics is constrained by various factors. Firstly, there is a shortage of well-equipped healthcare facilities with the necessary infrastructure and skilled personnel to perform tissue diagnostics accurately. Secondly, the high cost of diagnostic equipment, reagents, and maintenance can be prohibitive for healthcare institutions with limited budgets. Thirdly, geographical barriers and inadequate transportation infrastructure can impede patients' ability to reach healthcare centers that offer tissue diagnostic services, especially in remote rural areas. Additionally, a lack of awareness and education about the importance of early disease detection can lead to delayed healthcare-seeking behavior. Addressing limited accessibility in developing regions requires multifaceted efforts, including investments in healthcare infrastructure, training programs to build a skilled workforce, development of affordable and portable diagnostic technologies, and public health campaigns to raise awareness and encourage regular screenings. Overcoming these accessibility challenges is essential for ensuring that individuals in underserved regions have equitable access to tissue diagnostics, leading to earlier disease detection and improved healthcare outcomes.

Key Market Trends

Digital Pathology and AI Integration

Digital Pathology and AI Integration is a transformative trend in the Global Tissue Diagnostics Market. Digital pathology involves the digitization of traditional glass slides, enabling pathologists and healthcare professionals to view and analyze high-resolution histopathological images electronically. This shift from traditional microscopy to digital platforms allows for remote access, streamlined collaborations, and the creation of vast image archives. Moreover, the integration of artificial intelligence (AI) and machine learning algorithms enhances the diagnostic capabilities of digital pathology. AI-powered image analysis software can assist pathologists in identifying and quantifying tissue abnormalities, identifying specific biomarkers, and even predicting disease outcomes. These technologies improve diagnostic accuracy, reduce the risk of human error, and enable faster turnaround times, ultimately leading to more efficient and precise tissue diagnostics. Furthermore, AI-driven predictive analytics can help pathologists make more informed treatment recommendations by considering vast datasets and identifying subtle patterns that might be missed by the human eye. As the adoption of digital pathology and AI continues to grow, it not only enhances the quality of tissue diagnostics but also facilitates the development of large-scale databases for research and the delivery of pathology services to underserved areas through telepathology, making it a pivotal trend in advancing the field of tissue diagnostics.

Growing Telepathology

Telepathology is a crucial trend in the Global Tissue Diagnostics Market, revolutionizing the way pathology services are delivered and accessed. This approach involves the remote consultation and interpretation of pathology specimens, primarily histopathological images, by pathologists located at a distance from the patient or the specimen source. Telepathology leverages digital technology and high-speed internet connectivity to transmit high-resolution images, clinical data, and patient histories to remote pathologists for analysis. This trend offers several significant advantages, including improved access to specialized expertise and consultations regardless of geographical boundaries. It enhances collaboration among pathologists and facilitates second opinions on complex cases, ultimately leading to more accurate diagnoses and treatment decisions. Additionally, telepathology has proven particularly valuable in underserved and remote regions where access to experienced pathologists may be limited. It also supports healthcare systems in managing workloads efficiently by enabling pathologists to review cases remotely, thereby reducing turnaround times and enhancing overall patient care. As the demand for pathology services continues to grow, telepathology plays a pivotal role in addressing challenges related to access, expertise, and timely diagnosis, making it a transformative trend in the field of tissue diagnostics.

Segmental Insights

Application Insights

In 2022, the Tissue Diagnostics Market was dominated by the breast cancer segment and is predicted to continue expanding over the coming years. This is attributed due to the rising prevalence of cancer across various regions in the world, growing advanced technologies, and rising research initiatives.

Regional Insights

In 2022, the Global Tissue Diagnostics Market was dominated by the North America segment and is predicted to continue expanding over the coming years. This is ascribed due to rising cases cancer cases, rising development of cancer technology, and the growing healthcare infrastructure.

Key Market Players

  • Nanoscribe GmbH & Co. KG
  • Stratasys Ltd.
  • 3D Systems Inc.
  • EOS GmbH
  • Renishaw PLC
  • Exone Company.
  • Formlabs Inc.,
  • Materialise NV.
  • SLM Solutions Group AG
  • Oxferd Performance Materials, Inc.

Report Scope:

In this report, the Global Tissue Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Tissue Diagnostics Market, By Product:

  • Instruments and Reagents Consumables

Global Tissue Diagnostics Market, By Application:

  • Circulating Tumor Cells
  • Circulating Tumor DNA
  • Cell-free DNA

Global Tissue Diagnostics Market, By Technology:

  • Immunohistochemistry
  • In-Situ Hybridizations
  • Digital Pathology
  • Workflow Management
  • Others

Global Tissue Diagnostics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Tissue Diagnostics Market.

Available Customizations:

  • Global Tissue Diagnostics Market report with the given Market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Tissue Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments and Reagents, and Consumables)
    • 5.2.2. By Application (Breast Cancer, Prostate Cancer, Gastric Cancer, and Other Cancers)
    • 5.2.3. By Technology (Immunohistochemistry, In-Situ Hybridizations, Digital Pathology and Workflow Management, and Others)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Product
    • 5.3.2. By Application
    • 5.3.3. By Technology
    • 5.3.4. By Region

6. North America Tissue Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Technology
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tissue Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Technology
    • 6.3.2. Canada Tissue Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Technology
    • 6.3.3. Mexico Tissue Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Technology

7. Europe Tissue Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Technology
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Tissue Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Technology
    • 7.3.2. France Tissue Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Technology
    • 7.3.3. United Kingdom Tissue Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Technology
    • 7.3.4. Italy Tissue Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Technology
    • 7.3.5. Spain Tissue Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Technology

8. Asia-Pacific Tissue Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Technology
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Tissue Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Technology
    • 8.3.2. Japan Tissue Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Technology
    • 8.3.3. India Tissue Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Technology
    • 8.3.4. South Korea Tissue Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Technology
    • 8.3.5. Australia Tissue Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Technology

9. South America Tissue Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Technology
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Tissue Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Technology
    • 9.3.2. Argentina Tissue Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Technology
    • 9.3.3. Colombia Tissue Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Technology

10. Middle East and Africa Tissue Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Technology
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Tissue Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Technology
    • 10.3.2. Saudi Arabia Tissue Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Technology
    • 10.3.3. South Africa Tissue Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (As Reported)
  • 15.5. Recent Developments
    • 15.5.1. Nanoscribe GmbH & Co. KG
    • 15.5.2. Stratasys Ltd.
    • 15.5.3. 3D Systems Inc.
    • 15.5.4. EOS GmbH
    • 15.5.5. Renishaw PLC
    • 15.5.6. Exone Company.
    • 15.5.7. Formlabs Inc.,
    • 15.5.8. Materialise NV.
    • 15.5.9. SLM Solutions Group AG
    • 15.5.10. Oxferd Performance Materials, Inc.

16. Strategic Recommendations